When was Nanogenics founded?

Nanogenics was founded in 2011.

Where is Nanogenics located?

Nanogenics is headquartered in Selkirk, United Kingdom. It is registered at 2 HALL HOUSE GUILDFORD ROAD,LOXWOOD,BILLINGSHURST,ENGLAND,RH14 0SA.

Where does Nanogenics rank among its competitors?

Nanogenics ranks 2138th amongst 3414 active competitors, of which 1139 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Nanogenics?

Nanogenics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Nanogenics - 2026 Company Profile, Funding, Competitors & Financials

Q: Is Nanogenics an acquired company?

Nanogenics got acquired by N4 Pharma on Sep 28, 2023.

Nanogenics is an acquired company based in Selkirk (United Kingdom), founded in 2011. It operates as a Provider of RNA therapeutics to treat cancer and ophthalmic diseases. The company has 3414 active competitors, including 1139 funded and 785 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Provider of RNA therapeutics to treat cancer and ophthalmic diseases. The company specializes in the precision delivery of therapeutic RNAs, using proprietary gene delivery technology, LipTide to develop drugs for cancer and fibrosis. Its lead product, ECP-102, enhances chemotherapy by sensitizing cancer cells to cell death, and ECP-105 is glaucoma product that enhances the effectiveness of BLEB surgery.

Website: nanogenics.co.uk/en/
Social
Phone Number: +44 **********
Registered Address: 2 HALL HOUSE GUILDFORD ROAD,LOXWOOD,BILLINGSHURST,ENGLAND,RH14 0SA

Key Metrics

Founded Year

2011

Location

Selkirk, United Kingdom

Stage

Acquired

Investors

Braveheart Investment Group

Ranked

2138^th among 3414 active competitors

Similar Companies

Jazz Pharmaceuticals & 3039 more

Exit Details

Acquired by N4 Pharma (Sep 28, 2023)

View Nanogenics' full profile

Nanogenics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
NANOGENICS LIMITED CIN: 7636591 , United Kingdom, Active	May 16, 2011	-	-

Nanogenics got acquired by N4 Pharma on Sep 28, 2023 at an acquisition amount of $*****.

Click here to take a look at Nanogenics's acquisition in detail

Nanogenics is a funded company. Nanogenics has 1 institutional investor.

View details of Nanogenics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nanogenics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Nanogenics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
2138th	Nanogenics 2011, Selkirk (United Kingdom), Acquired	Provider of RNA therapeutics to treat cancer and ophthalmic diseases	-	Braveheart Investment Group	27/100